Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   10/07/2026
177,11 USD (-1,91%)
(-1,91%)   10/07/2026
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.
donderdag 30 juli 2026, 22:00
Kwartaalcijfers (2de kwartaal)

Neurocrine Biosciences, Inc. in het nieuws

9 juli 2026 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results · Persbericht

1 juli 2026 · Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia · Persbericht

15 juni 2026 · Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period · Persbericht

15 juni 2026 · Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 · Persbericht

15 juni 2026 · Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 · Persbericht

15 juni 2026 · Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 · Persbericht

8 juni 2026 · Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients · Persbericht

8 juni 2026 · Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities · Persbericht

3 juni 2026 · Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026 · Persbericht

26 mei 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in June · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

Mijn selecties